Rocket's Gene Therapy Clears Safety Hurdle; Shares Jump 7.5%
RCKT sits 34% above its 52-week low of $2.53.
Summary
Rocket's RP-A501 gene therapy for Danon disease showed no serious safety issues in the first three patients of its pivotal Phase 2 trial under a modified protocol. The company is now in active FDA discussions to align on dosing the remaining nine patients, with a regulatory update expected in the second half of 2026. Shares rose 7.5% on the news, reflecting optimism about the program's path forward. This follows the earlier BusinessWire report this morning and adds the market's positive reaction and details on FDA engagement.
At the time of this announcement, RCKT was trading at $3.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $369.6M. The 52-week trading range was $2.53 to $5.45. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.